Comprehensive analysis of clinical therapeutic effects of mirikizumab

Mirikizumab is a monoclonal antibody drug targeting interleukin-23 (IL-23p19). It is mainly used for the treatment of moderate to severe ulcerative colitis and Crohn's disease (CD). Its mechanism of action is by selectively inhibiting the IL-23-mediated inflammatory signaling pathway, reducing the activation of T cells and related inflammatory cells, thereby reducing the inflammatory response of the intestinal mucosa and helping to restore intestinal barrier function. Compared with traditional immunosuppressants, militizumab is more targeted and less likely to cause systemic immunosuppression, thereby reducing the risk of infection and systemic side effects.

In clinical practice, militizumab can improve patients' symptoms, including reducing the frequency of diarrhea, improving bloody stools, reducing defecation urgency, and relieving abdominal pain. At the same time, signs of mucosal repair can be observed during follow-up endoscopy. This has significant implications for the quality of life of patients, especially those refractory to conventional immunosuppressants or anti-TNF-α drugs, and militizumab provides a new treatment option. The drug can be administered intravenously or subcutaneously, and doctors can develop an individualized plan based on the patient's condition, compliance, and convenience.

In long-term follow-up, militizumab showed good mucosal repair ability, which is an important indicator for evaluating the efficacy of inflammatory bowel disease. Through continuous treatment, the patient's intestinal inflammatory activity can be controlled, the frequency of recurrence is reduced, and the quality of life is significantly improved. At the same time, side effects are mostly tolerable, and common ones include injection site reactions, mild upper respiratory tract infections, or mild gastrointestinal discomfort.

Overall, militizumab can provide both effective symptom control and long-term maintenance in the treatment of inflammatory bowel disease, allowing patients to achieve a higher quality of life in clinical management.

Reference materials:https://omvoh.lilly.com/